China: Food, Drugs, Healthcare, Life Sciences

Subscribe

Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.

Han Kun • Opinion | Interpretation Of China's Annual Drug Review Report (2015-2021) - Review Of The Reform Of Our Country's Drug Review And Approval System (Part II)

In "Interpretation of China's Annual Drug Review Report (2015-2021) - Review of the Achievements of China's Drug Review and Approval System Reform (Part 1)"...

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Interpretation Of China's Annual Drug Review Report (2015-2021) - Review Of The Reform Achievements Of Our Country's Drug Review And Approval System (Part II)

In the "Interpretation of China's Annual Drug Evaluation Report (2015-2021) - Review of the Achievements of China's Drug Evaluation and Approval System Reform (Part 1)", we have summarized and refined the key contents...

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | 医药BD项目如何友好"分手"？

医药BD(business development，商务拓展)项目通常指通过授权许可、投资、并购、合作开发/商业化等方式进行产品和技术的商业机会拓展。全球新冠疫情已逾三年，

China Healthcare

HK

Han Kun Law Offices

How Digital Therapeutics (DTx) Products Are Regulated In China?

This article discusses the regulation of DTx products in China, the question of registration, and best practices for collecting and processing data through DTx products.

China Healthcare

HK

Han Kun Law Offices

生命科学行业License-in/out合同争议要点分析（三）：不竞争条款

China Healthcare

HK

Han Kun Law Offices

2024 Data Analytics: China Life Sciences NewCo & Licensing Terms

China Healthcare

HK

Han Kun Law Offices

Strengthening Oversight of Imported Drugs: Key Takeaways into New Regulations on Domestic Responsible Entities

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | The New Ethical Review Regulations Focus On Quick Comments

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Hainan Boao Lecheng Clinical Urgently Needs A Review Of The Highlights Of The New Regulations On The Management Of Imported Drugs And Devices

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Key Points For The Supervision Of Medical And Three-Product And One-Device Advertising Under The New Regulations On Internet Advertising

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Brief Review Of The Measures For The Review Of Science And Technology Ethics (Trial) (Draft For Comments)

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | CAR-T/NK监管路在何方 — 体细胞临床研究工作指引（征求意见稿）要点解读

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Interpretation Of The New Administrative Guidelines For Human Genetic Resources

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Implementation And Regulation Of DCT (Decentralized Clinical Trials) In China

China Healthcare

HK

Han Kun Law Offices

观点 | 中美关税博弈对医药行业的影响快评

China International

HK

Han Kun Law Offices

국가지식산권국,허베이성의 "AI를 특허 전환 및 활용 촉진 시범사업"지원 승인

K

Kangxin

Beyond Stay Or Leave: How MNCs Are Recalibrating Their China Strategy (Video)

China Commercial

AM

Alvarez & Marsal

A Series Of Observations On Family Office Investment In Chinese Projects

China Commercial

Zhong Yin Law Firm

Exploring Optimal Solutions To Protect Trade Secrets —Based On Analysis Of The New Guidelines On Trade Secrets Protection

China International

AB

AnJie Broad Law Firm

See more

Food and Drugs Law

Han Kun • Opinion | Interpretation Of China's Annual Drug Review Report (2015-2021) - Review Of The Reform Of Our Country's Drug Review And Approval System (Part II)

In "Interpretation of China's Annual Drug Review Report (2015-2021) - Review of the Achievements of China's Drug Review and Approval System Reform (Part 1)"...

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Interpretation Of China's Annual Drug Review Report (2015-2021) - Review Of The Reform Achievements Of Our Country's Drug Review And Approval System (Part II)

In the "Interpretation of China's Annual Drug Evaluation Report (2015-2021) - Review of the Achievements of China's Drug Evaluation and Approval System Reform (Part 1)", we have summarized and refined the key contents...

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | 医药BD项目如何友好"分手"？

医药BD(business development，商务拓展)项目通常指通过授权许可、投资、并购、合作开发/商业化等方式进行产品和技术的商业机会拓展。全球新冠疫情已逾三年，

China Healthcare

HK

Han Kun Law Offices

How Digital Therapeutics (DTx) Products Are Regulated In China?

China Healthcare

HK

Han Kun Law Offices

生命科学行业License-in/out合同争议要点分析（三）：不竞争条款

China Healthcare

HK

Han Kun Law Offices

2024 Data Analytics: China Life Sciences NewCo & Licensing Terms

China Healthcare

HK

Han Kun Law Offices

Strengthening Oversight of Imported Drugs: Key Takeaways into New Regulations on Domestic Responsible Entities

China Healthcare

HK

Han Kun Law Offices

First Drug Patent Term Extension Granted In China

TM

Toby Mak

Han Kun • Opinion | Hainan Boao Lecheng Clinical Urgently Needs A Review Of The Highlights Of The New Regulations On The Management Of Imported Drugs And Devices

China Healthcare

HK

Han Kun Law Offices

See more

Life Sciences, Biotechnology & Nanotechnology

Han Kun • Opinion | Interpretation Of China's Annual Drug Review Report (2015-2021) - Review Of The Reform Of Our Country's Drug Review And Approval System (Part II)

In "Interpretation of China's Annual Drug Review Report (2015-2021) - Review of the Achievements of China's Drug Review and Approval System Reform (Part 1)"...

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Interpretation Of China's Annual Drug Review Report (2015-2021) - Review Of The Reform Achievements Of Our Country's Drug Review And Approval System (Part II)

In the "Interpretation of China's Annual Drug Evaluation Report (2015-2021) - Review of the Achievements of China's Drug Evaluation and Approval System Reform (Part 1)", we have summarized and refined the key contents...

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | 医药BD项目如何友好"分手"？

医药BD(business development，商务拓展)项目通常指通过授权许可、投资、并购、合作开发/商业化等方式进行产品和技术的商业机会拓展。全球新冠疫情已逾三年，

China Healthcare

HK

Han Kun Law Offices

How Digital Therapeutics (DTx) Products Are Regulated In China?

China Healthcare

HK

Han Kun Law Offices

生命科学行业License-in/out合同争议要点分析（三）：不竞争条款

China Healthcare

HK

Han Kun Law Offices

2024 Data Analytics: China Life Sciences NewCo & Licensing Terms

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Hainan Boao Lecheng Clinical Urgently Needs A Review Of The Highlights Of The New Regulations On The Management Of Imported Drugs And Devices

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Key Points For The Supervision Of Medical And Three-Product And One-Device Advertising Under The New Regulations On Internet Advertising

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Brief Review Of The Measures For The Review Of Science And Technology Ethics (Trial) (Draft For Comments)

China Healthcare

HK

Han Kun Law Offices

See more

Healthcare

汉坤 • 观点 | 医药BD项目如何友好"分手"？

医药BD(business development，商务拓展)项目通常指通过授权许可、投资、并购、合作开发/商业化等方式进行产品和技术的商业机会拓展。全球新冠疫情已逾三年，

China Healthcare

HK

Han Kun Law Offices

How Digital Therapeutics (DTx) Products Are Regulated In China?

This article discusses the regulation of DTx products in China, the question of registration, and best practices for collecting and processing data through DTx products.

China Healthcare

HK

Han Kun Law Offices

2024 Data Analytics: China Life Sciences NewCo & Licensing Terms

License-in/out transactions have become a key strategic approach for innovative drug and medical device (including medical aesthetics) companies to expedite the research and development of the products and expand market presence.

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | The New Ethical Review Regulations Focus On Quick Comments

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Hainan Boao Lecheng Clinical Urgently Needs A Review Of The Highlights Of The New Regulations On The Management Of Imported Drugs And Devices

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Brief Review Of The Measures For The Review Of Science And Technology Ethics (Trial) (Draft For Comments)

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | CAR-T/NK监管路在何方 — 体细胞临床研究工作指引（征求意见稿）要点解读

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Implementation And Regulation Of DCT (Decentralized Clinical Trials) In China

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | LDT试点新规解读

China Healthcare

HK

Han Kun Law Offices

See more

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More